| Applied concepts in PBPK modeling: how to build a PBPK/PD model L Kuepfer, C Niederalt, T Wendl, JF Schlender, S Willmann, J Lippert, ... CPT: pharmacometrics & systems pharmacology 5 (10), 516-531, 2016 | 297 | 2016 |
| Development of a whole-body physiologically based pharmacokinetic approach to assess the pharmacokinetics of drugs in elderly individuals JF Schlender, M Meyer, K Thelen, M Krauss, S Willmann, T Eissing, ... Clinical pharmacokinetics 55, 1573-1589, 2016 | 108 | 2016 |
| Open Systems Pharmacology Community—An Open Access, Open Source, Open Science Approach to Modeling and Simulation in Pharmaceutical Sciences J Lippert, R Burghaus, A Edginton, S Frechen, M Karlsson, A Kovar, ... CPT: pharmacometrics & systems pharmacology 8 (12), 878, 2019 | 73 | 2019 |
| Physiologically Based Pharmacokinetic Modeling of Monoclonal Antibodies in Pediatric Populations Using PK-Sim S Basu, YTK Lien, V Vozmediano, JF Schlender, T Eissing, S Schmidt, ... Frontiers in Pharmacology 11, 868, 2020 | 30 | 2020 |
| Predictive Pediatric Modeling and Simulation Using Ontogeny Information I Ince, J Solodenko, S Frechen, A Dallmann, C Niederalt, J Schlender, ... The Journal of Clinical Pharmacology 59, S95-S103, 2019 | 30 | 2019 |
| A physiologically-based pharmacokinetic model to describe ciprofloxacin pharmacokinetics over the entire span of life JF Schlender, D Teutonico, K Coboeken, K Schnizler, T Eissing, ... Clinical Pharmacokinetics 57, 1613-1634, 2018 | 29 | 2018 |
| Current strategies to streamline pharmacotherapy for older adults JF Schlender, V Vozmediano, AG Golden, M Rodriguez, TS Samant, ... European Journal of Pharmaceutical Sciences 111, 432-442, 2018 | 18 | 2018 |
| Data‐driven personalization of a physiologically based pharmacokinetic model for caffeine: A systematic assessment R Fendt, U Hofmann, ARP Schneider, E Schaeffeler, R Burghaus, ... CPT: pharmacometrics & systems pharmacology 10 (7), 782-793, 2021 | 16 | 2021 |
| Translational learning from clinical studies predicts drug pharmacokinetics across patient populations M Krauss, U Hofmann, C Schafmayer, S Igel, J Schlender, C Mueller, ... NPJ systems biology and applications 3 (1), 11, 2017 | 16 | 2017 |
| Predictive Performance of Physiology‐Based Pharmacokinetic Dose Estimates for Pediatric Trials: Evaluation With 10 Bayer Small‐Molecule Compounds in Children I Ince, A Dallmann, S Frechen, K Coboeken, C Niederalt, T Wendl, ... The Journal of Clinical Pharmacology 61, S70-S82, 2021 | 15 | 2021 |
| Arzneimittelinteraktionen im Alter K Bitter, JF Schlender, R Woltersdorf Der Internist 7 (57), 728-734, 2016 | 12 | 2016 |
| Geriatrics 2030: Developing Drugs to Care for Older Persons—A Neglected and Growing Population SWJ Lau, JF Schlender, PW Slattum, DL Heald, R O'Connor‐Semmes Clinical Pharmacology & Therapeutics 107 (1), 53-56, 2020 | 11 | 2020 |
| Early prediction of decompensation (EPOD) score: Non‐invasive determination of cirrhosis decompensation risk ARP Schneider, CV Schneider, KM Schneider, V Baier, S Schaper, ... Liver International 42 (3), 640-650, 2022 | 7 | 2022 |
| Improving therapeutics to better care for older adults and the young: report from the American College of Clinical Pharmacology workshop SWJ Lau, JF Schlender, DR Abernethy, GJ Burckart, A Golden, ... Journal of clinical pharmacology 58 (3), 277-280, 2018 | 6 | 2018 |
| Drug–drug interactions in the elderly: Which ones really matter? K Bitter, JF Schlender, R Woltersdorf Der Internist 57, 728-734, 2016 | 4 | 2016 |
| Physiologically Based Pharmacokinetic (PBPK) Modelling of Oral Drug Absorption in Older Adults–an AGePOP review C Demeester, D Robins, AE Edwina, J Tournoy, P Augustijns, I Ince, ... European Journal of Pharmaceutical Sciences, 106496, 2023 | 3 | 2023 |
| The personalization of drug therapy for elderly patients JF Schlender, AG Golden, TS Samant, CV Lagishetty, S Schmidt Developing Drug Products in an Aging Society: From Concept to Prescribing …, 2016 | 3 | 2016 |
| PBPK Modelling of Intracellular Drug Delivery Through Active and Passive Transport Processes L Kuepfer, C Niederalt, T Wendl, JF Schlender, M Block, T Eissing, ... Intracellular Delivery III: Market Entry Barriers of Nanomedicines, 363-374, 2016 | 3 | 2016 |
| PHYSIOLOGICALLY-BASED PHARMACOKINETIC AND CLINICAL STUDY TO ASSESS EFFECTS OF CYP3A INDUCTION AND INHIBITION ON COPANLISIB PK IN CANCER PATIENTS. JF Schlender, J Grevel, S Frechen, C Diedrich, R Burghaus, A Spreafico, ... CLINICAL PHARMACOLOGY & THERAPEUTICS 105, S70-S70, 2019 | 2 | 2019 |
| Physiologically-based pharmacokinetic modeling to inform dosing regimens and routes of administration of rifampicin and colistin combination against Acinetobacter baumannii J Zhang, C Song, M Wu, J Yue, S Zhu, P Zhu, OO Charles, JF Schlender, ... European Journal of Pharmaceutical Sciences 185, 106443, 2023 | 1 | 2023 |
Thomas EissingBayer AGBestätigte E-Mail-Adresse bei bayer.com
